Smart Cities Start With People, Not Technology: Study - NDTV

Johnny Hilbrant Partridge never worked an hour on Wall Street, but you’d never guess that by looking at him. Nearly every day, Partridge takes to YouTube to channel his inner finance bro as P. E. Guy, a puffer-vested private equity putz who brags about his million-dollar deals, Aspen manse and private plane. Partridge, who once taught fitness classes in Boston, debuted the character on social media last year, which boosted his following beyond Barry’s and SoulCycle devotees. Today, he has 400,000-plus Instagram followers, up from 7,000 about 18 months ago.

News|Articles|October 24, 2026 Baseline and on-treatment circulating tumor DNA (ctDNA) features, including TP53 mutations and methylation-based tumor fraction, were associated with early progression or prolonged progression-free survival (PFS) with first-line lorlatinib (Lorbrena) in patients with ALK-positive advanced non–small cell lung cancer (NSCLC), in exploratory analyses of the phase 3 CROWN trial (NCT03052608) presented at the 2026 European Society for Medical Oncology (ESMO) Congress.1Compared with long-term responders, who were progression free at 84 months (n = 30), early progressors, who had a PFS event within 12 months (n = 22), had a higher median number of altered genes at baseline (10 vs 6), a higher median blood-based tumor mutation burden (7.7 vs 5.1), and more frequent TP53 mutations (50% vs 17%). In the lorlatinib arm, the 7-year PFS rate was 65.0% (95% CI, 54.5%-77.4%) in patients with TP53 wild-type disease (n = 73) vs 40.8% (95% CI, 27.3%-61.1%) in those with TP53-mutated disease (n = 43; HR, 0.48; 95% CI, 0.268-0.857); median PFS was not reached (NR) vs 51.6 months (95% CI, 16.4-NR), respectively.

CML treatment has transformed long-term survival, allowing many patients receiving effective TKI therapy to achieve a life expectancy approaching that of the general population. Molecular response milestones guide personalized treatment decisions, helping clinicians assess treatment effectiveness, recognize inadequate responses, and adjust therapy when necessary.

It feels like Apple’s Welcome Home event just happened. And the iPhone Duo announcement isn’t all that far in our rearview mirror, either. Yet, the company is back with another launch, focused on the MacBook Pro, it looks like. Its “Pro and tell” event is scheduled for October 28th at 1PM ET in Los Angeles. While obviously nothing is confirmed yet, it sure seems like we’re finally going to get that long-rumored touchscreen MacBook Pro. Beyond that? There could be an OLED update for the iPad Mini, plus M6 updates across other devices, following the M6 debut with the Mac Mini in August. A touchscreen MacBook ProA MacBook Pro with an OLED touchscreen has been a fixture of the rumor mill since at least early 2023. But now, in late 2026, it may finally come to fruition. The name MacBook Ultra has been floating around, but Apple is unlikely to rebrand its flagship laptop line. This will be the first touchscreen laptop and the first OLED laptop from Apple. It will supposedly feature an iPhone-esque Dynamic Island, but don’t expect a dramatic revamp of the macOS interface — The touchscreen MacBook isn’t going to be some sort of iPad hybrid.

The $400 Boox Palma 2 Pro is a smartphone-sized e-reader designed for people who want to read books, articles, and documents on a small E Ink display. However, it offers more than just a dedicated reading experience because it runs Android and supports Google Play, giving you access to third-party apps. Think of it as a cross between a Kindle and a compact Android tablet. What drew me to reviewing the Palma 2 Pro was its size. When I’m not reading a physical book, I like to lie on my side and read at night before bed. Most e-readers are squarish and hard to hold without something like a PopSocket, and they can feel too big for reading while lying down. So even though I own a Kindle, I often ended up reading on my iPhone simply because it was more comfortable in my hand. But, reading on your phone for too long can of course cause eye strain. The Palma 2 Pro ultimately solved this problem for me during the two months I spent testing it.